Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

146 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Efgartigimod and Ravulizumab for Treating Acetylcholine Receptor Auto-antibody-Positive (AChR-Ab+) Generalized Myasthenia Gravis: Indirect Treatment Comparison.
van Steen C, Celico L, Spaepen E, Hagenacker T, Meuth SG, Ruck T, Smith AG, Bodicoat DH, de Francesco M, Iannazzo S. van Steen C, et al. Among authors: hagenacker t. Adv Ther. 2024 Jun;41(6):2486-2499. doi: 10.1007/s12325-024-02856-3. Epub 2024 Apr 20. Adv Ther. 2024. PMID: 38642198 Free PMC article. Clinical Trial.
Understanding the burden of refractory myasthenia gravis.
Schneider-Gold C, Hagenacker T, Melzer N, Ruck T. Schneider-Gold C, et al. Among authors: hagenacker t. Ther Adv Neurol Disord. 2019 Mar 1;12:1756286419832242. doi: 10.1177/1756286419832242. eCollection 2019. Ther Adv Neurol Disord. 2019. PMID: 30854027 Free PMC article. Review.
A Sum Score to Define Therapy-Refractory Myasthenia Gravis: A German Consensus.
Schroeter M, Berger B, Blaes F, Hagenacker T, Jander S, Kaiser J, Kalischewski P, Lee DH, Ruck T, Schara U, Urban P, Meisel A. Schroeter M, et al. Among authors: hagenacker t. J Cent Nerv Syst Dis. 2021 Feb 1;13:1179573521989151. doi: 10.1177/1179573521989151. eCollection 2021. J Cent Nerv Syst Dis. 2021. PMID: 33597816 Free PMC article.
Autoimmune glomerulonephritis in a multiple sclerosis patient after cladribine treatment.
Schönfelder K, Schuh H, Pfister F, Krämer J, Eisenberger U, Skuljec J, Hackert J, Ruck T, Pfeuffer S, Fleischer M, Gäckler A, Hagenacker T, Kribben A, Meuth SG, Kleinschnitz C, Pul R. Schönfelder K, et al. Among authors: hagenacker t. Mult Scler. 2021 Oct;27(12):1960-1964. doi: 10.1177/13524585211022719. Epub 2021 Jun 24. Mult Scler. 2021. PMID: 34165361 Free PMC article.
Eculizumab versus rituximab in generalised myasthenia gravis.
Nelke C, Schroeter CB, Stascheit F, Pawlitzki M, Regner-Nelke L, Huntemann N, Arat E, Öztürk M, Melzer N, Mergenthaler P, Gassa A, Stetefeld H, Schroeter M, Berger B, Totzeck A, Hagenacker T, Schreiber S, Vielhaber S, Hartung HP, Meisel A, Wiendl H, Meuth SG, Ruck T. Nelke C, et al. Among authors: hagenacker t. J Neurol Neurosurg Psychiatry. 2022 May;93(5):548-554. doi: 10.1136/jnnp-2021-328665. Epub 2022 Mar 4. J Neurol Neurosurg Psychiatry. 2022. PMID: 35246490 Free PMC article.
Independent risk factors for myasthenic crisis and disease exacerbation in a retrospective cohort of myasthenia gravis patients.
Nelke C, Stascheit F, Eckert C, Pawlitzki M, Schroeter CB, Huntemann N, Mergenthaler P, Arat E, Öztürk M, Foell D, Schreiber S, Vielhaber S, Gassa A, Stetefeld H, Schroeter M, Berger B, Totzeck A, Hagenacker T, Meuth SG, Meisel A, Wiendl H, Ruck T. Nelke C, et al. Among authors: hagenacker t. J Neuroinflammation. 2022 Apr 12;19(1):89. doi: 10.1186/s12974-022-02448-4. J Neuroinflammation. 2022. PMID: 35413850 Free PMC article.
Immunological consequences of cladribine treatment in multiple sclerosis: A real-world study.
Rolfes L, Pfeuffer S, Huntemann N, Schmidt M, Su C, Skuljec J, Aslan D, Hackert J, Kleinschnitz K, Hagenacker T, Pawlitzki M, Ruck T, Kleinschnitz C, Meuth SG, Pul R. Rolfes L, et al. Among authors: hagenacker t. Mult Scler Relat Disord. 2022 Aug;64:103931. doi: 10.1016/j.msard.2022.103931. Epub 2022 May 29. Mult Scler Relat Disord. 2022. PMID: 35690010 Free article.
Risk and course of COVID-19 in immunosuppressed patients with myasthenia gravis.
Stascheit F, Grittner U, Hoffmann S, Mergenthaler P, Schroeter M, Ruck T, Pawlitzki M, Blaes F, Kaiser J, Schara U, Della-Marina A, Thieme A, Hagenacker T, Jacobi C, Berger B, Urban PP, Knop KC, Schalke B, Lee DH, Kalischewski P, Wiendl H, Meisel A. Stascheit F, et al. Among authors: hagenacker t. J Neurol. 2023 Jan;270(1):1-12. doi: 10.1007/s00415-022-11389-0. Epub 2022 Sep 27. J Neurol. 2023. PMID: 36166068 Free PMC article.
Cell-mediated cytotoxicity within CSF and brain parenchyma in spinal muscular atrophy unaltered by nusinersen treatment.
Lu IN, Cheung PF, Heming M, Thomas C, Giglio G, Leo M, Erdemir M, Wirth T, König S, Dambietz CA, Schroeter CB, Nelke C, Siveke JT, Ruck T, Klotz L, Haider C, Höftberger R, Kleinschnitz C, Wiendl H, Hagenacker T, Meyer Zu Horste G. Lu IN, et al. Among authors: hagenacker t. Nat Commun. 2024 May 15;15(1):4120. doi: 10.1038/s41467-024-48195-3. Nat Commun. 2024. PMID: 38750052 Free PMC article.
146 results